GOUT. OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe treatment of acute gouty arthritis Describe.

Slides:



Advertisements
Similar presentations
GOUT Disease caused by tissue deposition of Monosodium urate crystals as a result of supersatuaration of extra cellular fluid with MSU.
Advertisements

Copyright © 2015 Cengage Learning® Chapter 15 Urinary System Drugs.
1. Describe the pathogenesis of hyperuricemia and gout Goup C1 Group C1.
N ON - STEROIDAL ANTI - INFLAMMATORY DRUGS. BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF.
TXF Caveat on urate levels Serum uric acid level may be normal at the time of an acute attack. Normal level does not rule out gout. May be better.
Purine degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Purine Degradation & Gout (Musculoskeletal Block)
Prepared by : Tamara Odeh Diana Jawhari Supervised by : Dr. Ola Ayesh.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 74 Drug Therapy of Gout.
Pharmacology-1 PHL nd Term 5 th Lecture By Abdelkader Ashour, Ph.D. Phone:
Gout.
GOUT. OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe treatment of acute gouty arthritis Describe.
Reginald D Sanders, MD LSU Clinical Pharmacology Drug Therapy of Gout.
Uric Acid Metabolism & Gout. Nucleic Acids Mononucleotide Base + Sugar + Phosphoric Acid Base: Purine or Pyrimidine Polynucleotide (DNA or RNA) Mononucleotides.
Familial metabolic disease Characterized by : Acute arthritis Uric stones in the kidneys Hyperuricemia.
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
Chapter 13 Agents Used to Treat Hyperuricemia and Gout.
Uric Acid Metabolism & Gout. Nucleic Acids Mononucleotide Base + Sugar + Phosphoric Acid Base: Purine or Pyrimidine Polynucleotide (DNA or RNA) Mononucleotides.
Uric Acid Metabolism & Gout
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
Gout Familial metabolic disease characterized by : Acute arthritis Uric acid stones in the kidneys Hyperuricemia.
GOUT TREATMENT. Gout prevalence doubled over the last 20 yrs. Factors? - longevity - diuretic use - low dose ASA - obesity - end stage renal disease -
Musculoskeletal Medications Osteoporosis Rheumatoid Arthritis Gout Muscle Spasms.
N ON - STEROIDAL ANTI - INFLAMMATORY DRUGS. OBJECTIVES At the end of the lecture the students should : Define NSAIDs Describe the classification of this.
Propionic acid derivatives Ibuprofen, naproxen, fenoprofen, flurbiprofen, oxaprozin,→ anti-inflammatory, analgesic, and antipyretic.  These drugs are.
GOUT.
CARBONIC ANHYDRASE INHIBITORS ACETAZOLAMIDE E It is a sulfonamide derivative. It is a sulfonamide derivative. noncompetitively but reversible inhibits.
Purine degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Gout Gouty Arthritis By Mike Parenteau.
Clinical Case #6 By Chen, chun-Yu (Kim) Chen, I -chun (Afra) Chen, I -chun (Afra)
Four Stages of Gout  Asymptomatic hyperuricemia Elevated levels of uric acid in the blood but no other symptoms Does not require treatment  Acute gout/Acute.
CHAPTER © 2012 The McGraw-Hill Companies, Inc. All rights reserved. 20 Nonopioid Analgesics, Nonsteroidal Antiinflammatories, and Antigout Drugs.
Slow Acting Anti-inflammatory Drugs ). BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSF.
Gout Familial metabolic disease characterized by : Acute arthritis Uric acid stones in the kidneys Hyperuricemia.
Agents Used to Treat Hyperuricemia and Gout
GOUT: DIAGNOSIS AND MANAGEMENT. Gout Metabolic disorder due to excessive accumulation of uric acid in tissues leading to acute and chronic arthritis and.
Drug Therapy of Gout. Drug therapy of gout What Is Gout?
Gout. The most common cause of inflammatory arthritis in US adults (3.9% of Americans; approx. 8.3 million people; ) Prevalence is greater in.
Angelo L Gaffo Kenneth G Saag Core Evidence 2009:4 25–36
Disease modified Anti-rheumatic drugs ( DMARD)
StagesClinical Features (1)Asymptomatic hyperuricemiahigh uric acid level is present but without symptoms (2) Acute Gouty Arthritishigh uric acid level.
GOUTY ARTHRITIS PRESENTED BY, JISMI MATHEW LINCY K OUSEPH MEENUPRIYA OONNANAL SMITHA V CHACKO VINEETHA MARY MATHEW.
Colchicine: Colchicine: Effective & specific gout Rx, but less favored than NSAIDs because of slow onset of action & high incidence of side effects. Effective.
GOUTY ARTHRITIS PRESENTED BY, JISMI MATHEW LINCY K OUSEPH MEENUPRIYA OONNANAL SMITHA V CHACKO VINEETHA MARY MATHEW.
Non-steroidal anti-inflammatory drugs
Gout Pharmacotherapies Joseph Kitzmiller MD PhD FCP 5086 Graves Hall Assistant Professor – Biological Chemistry & Pharmacology
ANTI-GOUT DRUGS. GOUT A familial metabolic disease characterized by recurrent episodes of acute arthritis due to deposits of monosodium urate in joints.
Drugs in gout epidemiology Male to female ration 10:1 Prevalence of hyperuricemia 5% Prevalence of gout 0.2%
Purine Degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Metabolism of purine nucleotides A- De Novo synthesis: of AMP and GMP Sources of the atoms in purine ring: N1: derived from NH2 group of aspartate C2 and.
Gout Ashley Guzman Primary Care I: Acute and Chronic Health Problems
Gout Is recurrent inflammatory disorder characterized by
Gout.
Drugs in gout epidemiology Prevalence of hyperuricemia 5%
Drugs in gout.
ليس العار في أن نسقط، ولكنّ العار ألا نستطيع النّهوض
Drug Therapy of Gout 1.
GOUT.
  URIC ACID Muthana A. Al-Shemeri.
Gout and Hyperuricaemia
Recent Advancement In Therapeutics ZURAMPIC ( LESINURAD)
Antiuricaemic drugs Dr A.W Olusanya.
Lecture 9 Musculoskeletal Disorders Gout
Gout and Hyperuricaemia
Drugs in gout epidemiology Prevalence of hyperuricemia 5%
Drugs in gout.
Presentation transcript:

GOUT

OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe treatment of acute gouty arthritis Describe the mechanism of action, clinical uses & side effects of drugs used in acute attacks

OBJECTIVES ( continue) Classify drugs used in chronic treatment Define each group of drugs Describe the mechanism of action, clinical uses & side effects & drug interactions for drugs used in chronic treatment

High blood uric acid levelMost uric acid is excreted by kidneysBlood  monosodium urate ♂>♀ Rare before puberty Breakdo wn of product of the body’s purine (nucleic acid) metaboli sm.

Aetiology of raised uric acid level Idiopathic decrease in uric acid excretion (75%) Increase uric acid production due to increased cell turn over (tumours), increase uric acid synthesis (specific enzyme defect) High dietary purine intake Impaired uric acid excretion secondary to thiazide diuretics, chronic renal failure

1 Asymptomatic Stage 2 Acute stage 3 Intercritical stage 4 Chronic stage

What is the treatment of gout ?

Broad lines in treatment of gout Non- pharmacologic pharmacologic Acute gouty arthritis Prevention of recurrent attack

Non-pharmacologic Therapy

DRUGS USED IN TEATMENT OF GOUT Most therapeutic strategies for gout involve lowering the uric acid level below the saturation point (<6 mg/dL), thus preventing the deposition of urate crystals. This can be accomplished by: 1.interfering with uric acid synthesis with allopurinol 2.increasing uric acid excretion with probenecid or sulfinpyrazone 3.inhibiting leukocyte entry into the affected joint with colchicine, 4.administration of NSAIDs Most therapeutic strategies for gout involve lowering the uric acid level below the saturation point (<6 mg/dL), thus preventing the deposition of urate crystals. This can be accomplished by: 1.interfering with uric acid synthesis with allopurinol 2.increasing uric acid excretion with probenecid or sulfinpyrazone 3.inhibiting leukocyte entry into the affected joint with colchicine, 4.administration of NSAIDs

Acute gouty arthritis NSAIDsColchicineCorticosteroid

NSAIDs drugs of choice for young, healthy adults without any other serious medical condition usually taken orally at their highest safe dosage as long as gout symptoms persist and for three or four days after low doses of NSAIDs may be used to prevent gout attacks, including in patients who are starting anti-hyperuricemic therapies.

2. Colchicine A plant alkaloid Used for the treatment of acute gouty attacks and prophylaxis Neither a uricosuric nor an analgesic agent, yet relieves pain in acute attacks of gout Prophylactic effect which reduces the frequency of acute attacks

MECHANISM OF ACTIONS Binds to tubulin > disrupt mobility of granulocytes to affected area Inhibits the synthesis and release of the leukotrienes B ₄ and interleukin-8 Decrease production of TNF- α by macrophages

PHARMACOKINETICS Administered orally, followed by rapid absorption from the GI tract Reaches peak plasma levels within 2 hoursAlso available combined with probenecid Recycled in the bile and is excreted unchanged in the faeces or urine. Use should be avoided in patients with a creatinine clearance of less than 50 mL/min. PHA PHARMACOKINETICS

THERAPEUTIC USES Treatment for Mediterranean Fever Colchicine is currently used for prophylaxis of recurrent attacks and will prevent attacks in more than 80 percent of patients. The anti-inflammatory activity of colchicine is specific for gout, usually alleviating the pain of acute gout within 12 hours

Adverse effects Diarrhea is a common adverse effect. May cause nausea, vomiting,abdominal cramps. Chronic use may cause, alopecia, bone marrow depression, peripheral neuritis, myopathy. Also, affect fertility

Prevention of recurrent attack Inhibition of uric acid synthesis Allopurinol Uricosuric drugs - Probenacid - Sulfinpyrazone

Inhibition of uric acid synthesis

Pharmacokinetics Well absorbed orally Bioavailability 53% Vd= 0.87l/kg Low protein binding metabolism is reported 76%. Renal Excretion accounts for 10% and plasma half life is 1.2 h

Severe tophaceous deposits (uric acid deposits in tissues) Therapeutic Uses

High serum uric acid in patients with impaired renal functions.

uric acid stones or nephropathy.

used to prevent increased uric acid levels in patients receiving cancer chemotherapy

ALLOPURINOL (SIDE EFFECTS AND DRUG INTERACTIONS)

Side Effects (most common) Prolong and exacerbation of an acute attack of gout

Maculopapular skin rash

nausea, diarrhea

Drug Interactions With oral anticoagulant: warfarin and dicumarol inhibits their metabolism

With anticancer : Reduce the metabolism of 6-mercaptopurine and azathioprine Requring reduction of Dosage up to 75%

With ampicillin : Increases frequency of skin rash Prolongs half life of Chlorpropamide both compete for excretion in renal tubule

Febuxostat Is a new oral non-purine xanthine oxidase (XO)inhibitor. Is structurally different from allopurinol& lacks purine ring More selective and potent inhibitor of XO than allopurinol & has no effect on other enzymes involved in purine or pyrimidine metabolism Well absorbed orally ( 84%) Can be given with or without food Given orally once daily Metabolized in liver & excreted in in the urine & faeces

Continue More effective than allopurinol in patients with impaired renal function; no dose adjustment is required in mild-to- moderate renal impairment Used for treatment of chronic hyperuricemia in gout patients Given to patients who do not tolerate allopurinol

Adverse effects Increase number of gout attacks during the first few months of treatment Increase level of liver enzymes Nausea, Diarrhea Headache Numbness of arm or leg

Uricosuric drugs

Uricosuric drugs ( probenecid, sulfinpyrazone, large dose of aspirin) decrease the reabsorption of uric acid & increase the amount excreted Mechanism of action

Clinical uses Chronic gout (urine volume should be maintained at a high level, and urinary pH kept alkaline ). Probenecid is used to prolong the action of some antibiotics e.g. penicillin.

Side effects Exacerbation of acute attack Risk of uric acid stone GIT upset Allergic rash

Contra-indication Previous urinary tract stone Impaired renal function Recent acute gout Co-administration of low dose aspirin

DRUG INTERACTIONS Aspirin can prevent probenecid from being fully effective

DRUG INTERACTIONS: Sulfinpyrazone can aggravate peptic ulcer disease Aspirin products can interfere with sulfinpyrazone's effects Sulfinpyrazone can enhance the action of certain diabetes medicines

Recombinant mammalian uricase Pegloticase Is a uric acid specific enzyme which is a recombinant modified mammalian uricase enzyme Converts uric acid to allantoin Given I.V.  peak decline in uric acid level within hours

Continue Used for the treatment of chronic gout in adult patients refractory to conventional therapy Adverse effects Infusion reactions Anaphylaxis Gout flare Nephrolithiasis Arthralgia, muscle spasm Headache

SUMMARY Gout is a form of arthritis that is characterized by sudden, severe attacks of pain, redness and tenderness. Gout is caused by deposits of uric acid crystals in a joint Uric acid is a waste product formed from the breakdown of purines.

SUMMARY ( continue) Treatment of gout includes : Treatment of acute attacks Prevention of future attacks Treatment of chronic gout

SUMMARY (continue) Drugs used for acute attacks includes : NSAIDs ( selective or non-selective) Colchicine interfere with the migration of granulocytes to the site of inflammation & reduce the release and synthesis of leukotriens Main adverse effects includes :

SUMMARY ( continue) Diarrhea Skin rash Kidney, liver & CNS injury Drugs used for chronic treatment includes : Uricosuric drugs that increase urinary excretion of uric acid

SUMMARY ( continue) Probenecid & sulfinpyrazone Their main adverse effects includes : Gastrointestinal problems Skin rashes Leukopenia Anti-hyperuricemic drugs that reduce the production of uric acid

SUMMARY ( continue) Allopurinol is an oxidase inhibitor Used in patients with elevated blood uric acid level Or in patients with tendency for renal stone formation Its main adverse effects includes : Gastric problems

SUMMARY ( continue) Skin rashes Leukopenia Thrombocytopenia Allopurinol reduces the metabolism of some drugs including azathioprime, this needs reduction of the doses of these drugs up to 75%